informCLL Registry Study for Chronic Lymphocytic Leukemia
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

informCLL Registry Study for Chronic Lymphocytic Leukemia

Sponsor: Pharmacyclics LLC.

The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens. This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL).